100% Sensitivity and 96% Specificity Urine Test for Bladder Cancer*
URO17
Bladder cancer is the 6th most common cancer in the USA, with over 81,000 new cases annually. There are currently over 6.7 million patients with hematuria who need an accurate and non-invasive diagnostic test.
Advancing Bladder Cancer Detection
The current gold standard for bladder cancer detection is cystoscopy
Exploring the Challenges
Cystoscopy is a painful and invasive procedure
Limitations
Confirmatory tests such as a CT scan, intravenous, pyelogram (IVP), X-ray, MRI, ultrasound, and urine cytology are also used but with limited utility
These challenges are why GoPath Diagnostics is excited to introduce the URO17 urine test for detecting bladder cancer.
The URO17 test is an immunocytochemical test based on a novel biomarker, with 100% sensitivity and 96% specificity* for detecting bladder cancer from urine samples.
The URO17 test is an immunocytochemical test based on a novel biomarker, with 100% sensitivity and 96% specificity* for detecting bladder cancer from urine samples.
Sensitive and Specific
The URO17 Urine test has 100% sensitivity
& 96% specificity.*
& 96% specificity.*
Compatible
Works with all standard immunohistochemistry systems, and detects high grade and low grade bladder cancer
Gold Standard Potential
Testing suggests that the URO17 test could improve the accuracy of cytology and cystoscopy in monitoring recurrence cases, and detection of new cases in patients with hematuria
How URO17 Compares with other Popular Urine Tests for Bladder Cancer
Sensitivity
Specificity
Cytology
NMP22
CX Bladder
UroVysion
Cystoscopy
56%
79%
82%
69%
98%
96%
84%
85%
78%
94%
URO17
*Babu et. al., Modern Pathology, 2019 May; 32(5):717-724
100%
96%
